The effectiveness of c-Abl inhibitors, particularly the highly specific Asciminib, in reducing pSer129 α-Syn levels and restoring normal transcriptional profiles underscores their potential to slow the progression of PD. The gene discussed is ABL1; the disease is Parkinson disease.